ArticleAmerican journal of cancer research2026
Therapeutic and prognostic value of repeat transurethral resection for high-grade Ta bladder cancer: a propensity score matching analysis.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade Ta bladder cancer, although anatomically confined to the mucosa, exhibits aggressive biological behavior with high recurrence rate and progression risks. The role of repeat transurethral resection of bladder tumor (Re-TURBT) in this specific population remains controversial. This retrospective cohort study aimed to evaluate the therapeutic and prognostic value of Re-TURBT for high-grade Ta non-muscle-invasive bladder cancer (NMIBC) using propensity score matching (PSM) analysis. A total of 324 patients with pathologically confirmed high-grade Ta urothelial carcinoma who underwent initial TURBT from January 2014 to June 2023 were included in this study. Among them, 196 underwent Re-TURBT within 2-6 weeks, whereas 128 did not. PSM was performed in a 1:1 ratio using a caliper width of 0.10, resulting in 70 matched pairs with comparable baseline characteristics. Recurrence-free survival (RFS) was defined as primary outcome. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and the residual tumor detection rate. In the Re-TURBT group, residual tumor was detected in 29.6% of patients, with pathological upstaging observed in 8.6% of cases (7.1% to T1 and 1.5% to T2). The Re-TURBT group showed significantly lower recurrence rates (14.3% vs. 50.0%; P<0.001) and progression rates (4.3% vs. 15.7%; P=0.024). Cox regression identified Re-TURBT as an independent protective factor for RFS (HR=0.217, 95% CI: 0.107-0.439, P<0.001) and PFS (HR=0.253, 95% CI: 0.070-0.906, P=0.023); however, Re-TURBT was not significantly associated with OS (P=0.854). Subgroup analyses revealed that the benefits of Re-TURBT were particularly pronounced in patients with larger tumors (>3.2 cm) and those not receiving BCG maintenance therapy. The overall complication rate was 6.12%. All complications were mild to moderate and were managed conservatively. To sum up, in patients with high grade Ta bladder cancer, Re-TURBT significantly reduces the risks of recurrence and progression and should be considered an integral component of high-risk NMIBC management, particularly for patients with larger tumors or suboptimal BCG maintenance therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.